Molecular Docking of Resveratrol with Ovarian Cancer-associated Proteins and Its Therapeutic Benefits

Yiwei Chen; Dayi Pan; Neil Roberts; Bomeng Du; Mingzhu Zheng; Zhilin Qian; Shangwen Jin; Jixia Wei; Fang Wan; Bensheng Qiu; Yaying Li

doi:10.14218/FIM.2025.00025

›› 2025, Vol. 4 ›› Issue (4) :204 -216. DOI: 10.14218/FIM.2025.00025

Review Article

research-article

Molecular Docking of Resveratrol with Ovarian Cancer-associated Proteins and Its Therapeutic Benefits

Author information +

History +

PDF

Abstract

Ovarian cancer (OC) is a major global health problem. The main treatments are surgery and chemoradiotherapy. A drawback of the latter is that repeated treatments are likely to lead to cancer cells developing resistance to the drug, resulting in recurrence, development of metastases, and poor prognosis for patients. Consequently, there is interest in combining chemoradiotherapy with treatment using active components extracted from natural products. One such component is resveratrol (RVT), which is a natural anti-tumor ingredient extracted from plants. Although there are many reviews on the biological activity of RVT, only a few studies have been performed to investigate the diversity of protein binding of RVT with OC and the application of various novel drug formulations containing RVT to treat OC. The review presented here may provide some ideas for the prevention and treatment of OC.

Keywords

Ovarian cancer / Resveratrol / Chemical sensitization / Drug delivery / Mo-lecular docking / Cancer therapy

Cite this article

Download citation ▾

Yiwei Chen, Dayi Pan, Neil Roberts, Bomeng Du, Mingzhu Zheng, Zhilin Qian, Shangwen Jin, Jixia Wei, Fang Wan, Bensheng Qiu, Yaying Li. Molecular Docking of Resveratrol with Ovarian Cancer-associated Proteins and Its Therapeutic Benefits. , 2025, 4(4): 204-216 DOI:10.14218/FIM.2025.00025

登录浏览全文

4963

注册一个新账户忘记密码

Acknowledgments

None.

Funding

This work was supported by the Guizhou Provincial Administration of Traditional Chinese Medicine Science and Technology Project of Traditional Chinese Medicine and Ethnic Medicine (QZYY-2025-015), Guizhou Provincial Science and Technology Projects (Qiankehe Foundation [2024] Youth 304), and the Science and Technology Support Program of the Department of Science and Technology of Guizhou Province, (Fund No. Qiankehe Support [2025] General 124).

Conflict of interest

The authors have no conflict of interest related to this publication.

Author contributions

Conceptualization, writing original draft (YC, DP), analysis and interpretation of data (BD, MZ, ZQ), critical revision of the manu-script for important intellectual content (NR, BQ), data curation (JW, FW, SJ), supervision, and project administration (YL). All authors have made significant contributions to this study and have approved the final manuscript.

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front Immunol 2019;10:1782. doi:10.3389/fim-mu.2019.01782,PMID:31456796.

[2]	Siegel RL, Giaquinto AN, Jemal A.Cancer statistics, 2024. CA Cancer J Clin 2024;74(1):12-49. doi:10.3322/caac.21820,PMID:38230766.

[3]	Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS. Surgical prevention strategies in ovarian cancer. Gynecol Oncol 2018; 151(1):166-175. doi:10.1016/j.ygyno.2018.08.005,PMID:30087058.

[4]	Stewart SL, Rim SH, Richards TB. Gynecologic oncologists and ovarian cancer treatment: avenues for improved survival. J Womens Health (Larchmt) 2011; 20(9):1257-1260. doi:10.1089/jwh.2011.3053,PMID:21819252.

[5]

Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, et al. Time to diagnosis of Type I or II invasive epithelial ovar-ian cancers: a multicentre observational study using patient ques-tionnaire and primary care records. BJOG 2016; 123(6):1012-1020. doi:10.1111/1471-0528.13447,PMID:26032603.

[6]	Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembeck-er M, et al. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem 2022;237:114346. doi:10.1016/j.ejmech.2022.114346,PMID:35483322.

[7]	Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, et al. Chemotherapy resistance in epithelial ovarian cancer: Mecha-nisms and emerging treatments. Semin Cancer Biol 2021; 77:144-166. doi:10.1016/j.semcancer.2021.08.011,PMID:34464704.

[8]	Yousef M, Vlachogiannis IA, Tsiani E. Effects of Resveratrol against Lung Cancer: In Vitro and In Vivo Studies. Nutrients 2017; 9(11):1231. doi:10.3390/nu9111231,PMID:29125563.

[9]	Fenner A. Prostate cancer: Resveratrol inhibits the AR. Nat Rev Urol 2017; 14(11):642. doi:10.1038/nrurol.2017.159,PMID:28976500.

[10]	Xu XL, Deng SL, Lian ZX, Yu K. Resveratrol Targets a Variety of Onco-genic and Oncosuppressive Signaling for Ovarian Cancer Prevention and Treatment. Antioxidants (Basel) 2021; 10(11):1718. doi:10.3390/antiox10111718,PMID:34829589.

[11]	Angellotti G, Di Prima G, Belfiore E, Campisi G, De Caro V. Chemopre-ventive and Anticancer Role of Resveratrol against Oral Squamous Cell Carcinoma. Pharmaceutics 2023; 15(1):275. doi:10.3390/pharmaceu-tics15010275,PMID:36678905.

[12]	Campos-Toimil M, Elíes J, Alvarez E, Verde I, Orallo F. Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes. Eur J Pharmacol 2007; 577(1-3):91-99. doi:10.1016/j.ejphar.2007.08.003,PMID:17822692.

[13]	Neyra Recky JR, Gaspar Tosato M, Buglak AA, Dántola ML, Lorente C. Photosensitized isomerization of resveratrol: Evaluation of energy and electron transfer pathways. Free Radic Biol Med 2024; 216:50-59. doi:10.1016/j.freeradbiomed.2024.01.038,PMID:38272325.

[14]	Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK, Ding L, et al. Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Lett 2021; 515:63-72. doi:10.1016/j.canlet.2021.05.001,PMID:34052324.

[15]	Réthoré L, Guihot AL, Grimaud L, Proux C, Barré B, Guillonneau F, et al. A Novel Function of Na(V) Channel β3 Subunit in Endothelial Cell Align-ment Through Autophagy Modulation. FASEB J 2025; 39(11):e70663. doi:10.1096/fj.202401558RR, PMID:40445729.

[16]	Lohse I, Wildermuth E, Brothers SP. Naturally occurring compounds as pancreatic cancer therapeutics. Oncotarget 2018; 9(83):35448-35457. doi:10.18632/oncotarget.26234,PMID:30459936.

[17]	Thipe VC, Raphael Karikachery A, Katti K, Katti KV. Immunomodula-tory and tumor-targeting palladium nanoparticles functionalized with resveratrol via green nanotechnology: synthesis, mechanisms, and in vivo therapeutic evaluation. J Mater Chem B 2025; 13(29):8683-8704. doi:10.1039/D5TB00620A.

[18]	Wang F, Chatterjee S. Dominant Carbons in trans- and cis-Resveratrol Isomerization. J Phys Chem B 2017; 121(18):4745-4755. doi:10.1021/acs.jpcb.7b02115,PMID:28402662.

[19]	Liu M, Liu T, Shi Y, Zhao Y, Yan H, Sun B, et al. Comparative study on the interaction of oxyresveratrol and piceatannol with trypsin and lysozyme: binding ability, activity and stability. Food Funct 2019; 10(12):8182-8194. doi:10.1039/c9fo01888c,PMID:31696185.

[20]	Hu Q, Luo Y. Polyphenol-chitosan conjugates: Synthesis, charac-terization, and applications. Carbohydr Polym 2016; 151:624-639. doi:10.1016/j.carbpol.2016.05.109,PMID:27474608.

[21]	Vittorio O, Curcio M, Cojoc M, Goya GF, Hampel S, Iemma F, et al. Poly-phenols delivery by polymeric materials: challenges in cancer treat-ment. Drug Deliv 2017; 24(1):162-180. doi:10.1080/10717544.2016.1236846,PMID:28156178.

[22]	Cirillo G, Curcio M, Vittorio O, Iemma F, Restuccia D, Spizzirri UG, et al. Polyphenol Conjugates and Human Health: A Perspective Review. Crit Rev Food Sci Nutr 2016; 56(2):326-337. doi:10.1080/10408398.2012.752342,PMID:24867371.

[23]	Paggi JM, Pandit A, Dror RO. The Art and Science of Molecular Dock-ing. Annu Rev Biochem 2024; 93(1):389-410. doi:10.1146/annurev-biochem-030222-120000,PMID:38594926.

[24]	Yang X, Potts PR. CSAG 2 is a cancer-specific activator of SIRT1. EMBO Rep 2020; 21(9):e50912. doi:10.15252/embr.202050912,PMID:32761762.

[25]	Wang S, Zhang J, Ma L inventors; Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, assignee. The application of SIRT 1 in the preparation of drugs for pro-tecting ovarian function. China patent CN112933215A. 2021 Jun 11.

[26]	Roy S, Das A, Vernekar M, Das S, Chatterjee N. Abstract 2461: SIRT1 regulates ovarian cancer metastasis via altering the exosome re-lease and glycogen deposition. Cancer Res 2021; 81(13_Suppl):2461. doi:10.1158/1538-7445. AM2021-2461.

[27]	Rayalam S, Della-Fera MA, Baile CA. Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis. Mol Nutr Food Res 2011; 55(8):1177-1185. doi:10.1002/mnfr.201000616,PMID:21538845.

[28]	Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al. Expres-sion and prognostic significance of SIRT 1 in ovarian epithelial tumours. Pathology 2009; 41(4):366-371. doi:10.1080/00313020902884451,PMID:19404850.

[29]	Sevgin K, Erguven P. SIRT1 overexpression by melatonin and res-veratrol combined treatment attenuates premature ovarian failure through activation of SIRT1/FOXO3a/BCL2 pathway. Biochem Biophys Res Commun 2024;696:149506. doi:10.1016/j.bbrc.2024.149506,PMID:38224665.

[30]	Kwon KJ, Kim HJ, Shin CY, Han SH. Melatonin Potentiates the Neuropro-tective Properties of Resveratrol Against Beta-Amyloid-Induced Neu-rodegeneration by Modulating AMP-Activated Protein Kinase Path-ways. J Clin Neurol 2010; 6(3):127-137. doi:10.3988/jcn.2010.6.3.127,PMID:20944813.

[31]	Bagul PK, Dinda AK, Banerjee SK. Effect of resveratrol on sirtuins ex-pression and cardiac complications in diabetes. Biochem Biophys Res Commun 2015; 468(1-2):221-227. doi:10.1016/j.bbrc.2015.10.126,PMID:26518647.

[32]	Wang R, Yuan W, Li L, Lu F, Zhang L, Gong H, et al. Resveratrol amelio-rates muscle atrophy in chronic kidney disease via the axis of SIRT1/FoxO1. Phytother Res 2022; 36(8):3265-3275. doi:10.1002/ptr.7499,PMID:35606908.

[33]	Saqib U, Kelley TT, Panguluri SK, Liu D, Savai R, Baig MS, et al. Polyphar-macology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets. Front Pharmacol 2018;9:1201. doi:10.3389/fphar.2018.01201,PMID:30405416.

[34]	Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, et al. Emerging roles for phospholipase A 2 enzymes in cancer. Biochim-ie 2010; 92(6):601-610. doi:10.1016/j.biochi.2010.03.019,PMID:20362028.

[35]	Amalinei C, Păvăleanu I, Balan RA. Involvement of phospholipase A2 in gynecological cancer. In: Chakraborti S (ed). Phospholipases in Physiol-ogy and Pathology. Vol 3. Amsterdam: Academic Press; 2023:15-37. doi:10.1016/B978-0-323-95697-0.00017-0.

[36]	Gao Y, Yang Z, Bajpai AK, Wang W, Zhang L, Xia Z. Resveratrol en-hances the antiliver cancer effect of cisplatin by targeting the cell membrane protein PLA2. Front Oncol 2024;14:1453164. doi:10.3389/fonc.2024.1453164,PMID:39381045.

[37]	Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB.Constitutive and lysophosphatidic acid (LPA)-induced LPA production:role of phospho-lipase D and phospholipase A2. Clin Cancer Res 2000; 6(6):2482-2491. PMID:10873103.

[38]	Ray U, Roy D, Jin L, Thirusangu P, Staub J, Xiao Y, et al. Group III phospho-lipase A2 downregulation attenuated survival and metastasis in ovar-ian cancer and promotes chemo-sensitization. J Exp Clin Cancer Res 2021; 40(1):182. doi:10.1186/s13046-021-01985-9,PMID:34082797.

[39]	Sharifpour S, Fakhraee S, Behjatmanesh-Ardakani R. Insights into the mechanism of inhibition of phospholipase A2 by resveratrol: An extensive molecular dynamics simulation and binding free energy calculation. J Mol Graph Model 2020;100:107649. doi:10.1016/j.jmgm.2020.107649, PMID:32739638.

[40]	Shukla PK, Gautam L, Sinha M, Kaur P, Sharma S, Singh TP. Structures and binding studies of the complexes of phospholipase A2 with five in-hibitors. Biochim Biophys Acta 2015; 1854(4):269-277. doi:10.1016/j.bbapap.2014.12.017, PMID:25541253.

[41]	Chan KKL, Siu MKY, Jiang YX, Wang JJ, Wang Y, Leung THY, et al. Dif-ferential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and progno-sis. BMC Cancer 2017; 17(1):606. doi:10.1186/s12885-017-3601-1,PMID:28859612.

[42]	Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013;14(9):853-862. doi:10.1016/S1470-2045(13)70253-5, PMID: 23845225.

[43]	Li S, Jiang K, Li J, Hao X, Chu W, Luo C, et al. Estrogen enhances the proliferation and migration of ovarian cancer cells by activating tran-sient receptor potential channel C3. J Ovarian Res 2020; 13(1):20. doi:10.1186/s13048-020-00621-y,PMID:32087757.

[44]	Kozieł MJ, Piastowska-Ciesielska AW. Estrogens, Estrogen Recep-tors and Tumor Microenvironment in Ovarian Cancer. Int J Mol Sci 2023; 24(19):14673. doi:10.3390/ijms241914673,PMID:37834120.

[45]	Qasem RJ. The estrogenic activity of resveratrol: a comprehensive re-view of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol 2020; 50(5):439-462. doi:10.1080/10408444.2020.1762538,PMID:32744480.

[46]	Chakraborty S, Levenson AS, Biswas PK. Structural insights into Res-veratrol’s antagonist and partial agonist actions on estrogen receptor alpha. BMC Struct Biol 2013; 13:27. doi:10.1186/1472-6807-13-27,PMID:24160181.

[47]	Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, et al. Cel-lular and molecular consequences of peroxisome proliferator-acti-vated receptor-gamma activation in ovarian cancer cells. Neoplasia 2006; 8(10):851-861. doi:10.1593/neo.06433,PMID:17032502.

[48]	Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 2011; 108(8):1002-1016. doi:10.1161/CIRCRESAHA.110.226860,PMID:21493923.

[49]	Prat M, Coulson K, Blot C, Jacquemin G, Romano M, Renoud ML, et al. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression. J Immunother Cancer 2023; 11(8):e007031. doi:10.1136/jitc-2023-007031,PMID:37586764.

[50]	Alhakamy NA, Alamoudi AJ, Abdulaal WH, Choudhry H, Asfour HZ, Al-Rabia MW, et al. Celastrol protects against cisplatin-induced ovarian toxicity via modulation of PPAR-γ and AMPK. Naunyn Schmiedebergs Arch Pharmacol 2025; 398(12):17267-17276. doi:10.1007/s00210-025-04322-5,PMID:40481255.

[51]	Yu YH, Chang YC, Su TH, Nong JY, Li CC, Chuang LM. Prostaglandin reductase-3 negatively modulates adipogenesis through regulation of PPARγ activity. J Lipid Res 2013; 54(9):2391-2399. doi:10.1194/jlr.M037556,PMID:23821743.

[52]	Calleri E, Pochetti G, Dossou KSS, Laghezza A, Montanari R, Capelli D, et al. Resveratrol and its metabolites bind to PPARs. Chembio-chem 2014; 15(8):1154-1160. doi:10.1002/cbic.201300754,PMID:24796862.

[53]	Zinger A, Cho WC, Ben-Yehuda A. Cancer and Aging - the Inflam-matory Connection. Aging Dis 2017; 8(5):611-627. doi:10.14336/AD.2016.1230,PMID:28966805.

[54]	Tang F, Wang Y, Hemmings BA, Rüegg C, Xue G. PKB/Akt-dependent regulation of inflammation in cancer. Semin Cancer Biol 2018; 48:62-69. doi:10.1016/j.semcancer.2017.04.018,PMID:28476657.

[55]	Yang L, Lin PC. Mechanisms that drive inflammatory tumor microen-vironment, tumor heterogeneity, and metastatic progression. Semin Cancer Biol 2017; 47:185-195. doi:10.1016/j.semcancer.2017.08.001,PMID:28782608.

[56]	Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8(2):217-225. doi:10.1096/fase-bj.8.2.8119492,PMID:8119492.

[57]	Kim KT, Heo JB, Roh T, Jeon SM, Heo HJ, Choi YJ, et al. Resveratrol derivative SH-707 inhibits NLRP3 inflammasome activation via a sir-tuin 1-dependent pathway. Int Immunopharmacol 2025;161:115049. doi:10.1016/j.intimp.2025.115049,PMID:40523327.

[58]	Zhong LM, Zong Y, Sun L, Guo JZ, Zhang W, He Y, et al. Resveratrol inhibits inflammatory responses via the mammalian target of rapa-mycin signaling pathway in cultured LPS-stimulated microglial cells. PLoS One 2012; 7(2):e32195. doi:10.1371/journal.pone.0032195,PMID:22363816.

[59]

Pinheiro DML, de Oliveira AHS, Coutinho LG, Fontes FL, de Medei-ros Oliveira RK, Oliveira TT, et al. Resveratrol decreases the expres-sion of genes involved in inflammation through transcriptional regulation. Free Radic Biol Med 2019; 130:8-22. doi:10.1016/j.freerad-biomed.2018.10.432,PMID:30366059.

[60]	Panaro MA, Carofiglio V, Acquafredda A, Cavallo P, Cianciulli A. Anti-inflammatory effects of resveratrol occur via inhibition of lipopoly-saccharide-induced NF-κB activation in Caco-2 and SW480 human colon cancer cells. Br J Nutr 2012; 108(9):1623-1632. doi:10.1017/S0007114511007227,PMID:22251620.

[61]	Ma C, Wang Y, Dong L, Li M, Cai W. Anti-inflammatory effect of res-veratrol through the suppression of NF-κB and JAK/STAT signaling pathways. Acta Biochim Biophys Sin (Shanghai) 2015; 47(3):207-213. doi:10.1093/abbs/gmu135,PMID:25651848.

[62]	Dalal V, Kumar R, Kumar S, Sharma A, Kumar L, Sharma JB, et al. Bio-marker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovar-ian cancer patients. Clin Chim Acta 2018; 482:27-32. doi:10.1016/j.cca.2018.03.019, PMID:29572186.

[63]	Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G, et al. Resveratrol inhibits IL-6-induced ovarian cancer cell migra-tion through epigenetic up-regulation of autophagy. Mol Carcinog 2017; 56(3):1164-1181. doi:10.1002/mc.22582,PMID:27787915.

[64]

Wang T, Wu F, Jin Z, Zhai Z, Wang Y, Tu B, et al. Plumbagin inhibits LPS-induced inflammation through the inactivation of the nuclear factor-kappa B and mitogen activated protein kinase signaling pathways in RAW 264.7 cells. Food Chem Toxicol 2014; 64:177-183. doi:10.1016/j.fct.2013.11.027, PMID:24296134.

[65]	Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 1999; 126(3):673-680. doi:10.1038/sj.bjp.0702357,PMID:10188978.

[66]	Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative mal-adies or just a fad? Mutat Res 2008; 658(1-2):68-94. doi:10.1016/j.mr-rev.2007.08.004,PMID:17890139.

[67]	Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23(12):2369-2380. doi:10.1038/sj.emboj.7600244,PMID:15152190.

[68]	Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25(6):280-288. doi:10.1016/j.it.2004.03.008,PMID:15145317.

[69]	Hayes JD, Dinkova-Kostova AT, Tew KD. Oxidative Stress in Cancer. Cancer Cell 2020; 38(2):167-197. doi:10.1016/j.ccell.2020.06.001,PMID:32649885.

[70]	Lin BW, Gong CC, Song HF, Cui YY. Effects of anthocyanins on the pre-vention and treatment of cancer. Br J Pharmacol 2017; 174(11):1226-1243. doi:10.1111/bph.13627,PMID:27646173.

[71]	Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, et al. ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. On-cogene 2023; 42(20):1672-1684. doi:10.1038/s41388-023-02679-6,PMID:37020040.

[72]	Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herb-al sources of resveratrol. J Agric Food Chem 2002; 50(11):3337-3340. doi:10.1021/jf0112973,PMID:12010007.

[73]	Seino M, Okada M, Shibuya K, Seino S, Suzuki S, Takeda H, et al. Dif-ferential contribution of ROS to resveratrol-induced cell death and loss of self-renewal capacity of ovarian cancer stem cells. Anticancer Res 2015; 35(1):85-96. PMID:25550538.

[74]

Ibrahim MA, Albahlol IA, Wani FA, Abd-Eltawab Tammam A, Kelleni MT, Sayeed MU, et al. Resveratrol protects against cisplatin-induced ovar-ian and uterine toxicity in female rats by attenuating oxidative stress, inflammation and apoptosis. Chem Biol Interact 2021;338:109402. doi:10.1016/j.cbi.2021.109402,PMID:33587916.

[75]	Hu X, Yuan Z, Huang G, Chen M, Chen T, He L. High-Valence seleni-um nanotherapeutics downregulates MUC16 to drive precise ovar-ian cancer therapy through redox perturbation. Adv Funct Mater 2025; 35(22):2419242. doi:10.1002/adfm.202419242.

[76]	Gu T, Wang N, Wu T, Ge Q, Chen L. Antioxidative stress mecha-nisms behind resveratrol: a multidimensional analysis. J Food Qual 2021; 2021(1): 5571733. doi:10.1155/2021/5571733.

[77]	Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther 2017; 173:83-105. doi:10.1016/j.pharmthera.2017.02.008,PMID:28174091.

[78]	Huang KC, Yang J, Ng MC, Ng SK, Welch WR, Muto MG, et al. Cyc-lin A1 expression and paclitaxel resistance in human ovarian cancer cells. Eur J Cancer 2016; 67:152-163. doi:10.1016/j.ejca.2016.08.007,PMID:27669502.

[79]	Vergara D, Simeone P, Toraldo D, Del Boccio P, Vergaro V, Leporatti S, et al. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol Biosyst 2012; 8(4):1078-1087. doi:10.1039/c2mb05486h,PMID:22234583.

[80]	Thaklaewphan P, Wikan N, Potikanond S, Nimlamool W. Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT). Biomolecules 2024; 14(9):1140. doi:10.3390/biom14091140,PMID:39334906.

[81]

Hankittichai P, Thaklaewphan P, Wikan N, Ruttanapattanakul J, Poti-kanond S, Smith DR, et al. Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Ad-enocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Sup-pressing AKT. Pharmaceuticals (Basel) 2023; 16(5):755. doi:10.3390/ph16050755,PMID:37242538.

[82]	Zhong LX, Li H, Wu ML, Liu XY, Zhong MJ, Chen XY, et al. Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells. J Ovarian Res 2015; 8:25. doi:10.1186/s13048-015-0152-4,PMID:25896424.

[83]

Wahba J, Natoli M, Whilding LM, Parente-Pereira AC, Jung Y, Zona S, et al. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovar-ian cancer. Cancer Immunol Immunother 2018; 67(11):1753-1765. doi:10.1007/s00262-018-2199-8,PMID:30167862.

[84]	Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, et al. Specific structural determinants are responsible for the anti-oxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001; 276(25):22586-22594. doi:10.1074/jbc.M101846200,PMID:11316812.

[85]	Liu Y, Tong L, Luo Y, Li X, Chen G, Wang Y. Resveratrol inhibits the prolif-eration and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway. J Cell Biochem 2018; 119(7):6162-6172. doi:10.1002/jcb.26822,PMID:29663499.

[86]	de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res 2005; 49(5):405-430. doi:10.1002/mnfr.200500022,PMID:15832402.

[87]	Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxy-genase regulates angiogenesis induced by colon cancer cells. Cell 1998;93(5):705-716. doi:10.1016/s0092-8674(00)81433-6, PMID:963 0216.

[88]	Lin C, Crawford DR, Lin S, Hwang J, Sebuyira A, Meng R, et al. Induc-ible COX-2-dependent apoptosis in human ovarian cancer cells. Car-cinogenesis 2011; 32(1):19-26. doi:10.1093/carcin/bgq212,PMID:21187340.

[89]	Lin HY, Tang HY, Davis FB, Davis PJ. Resveratrol and apoptosis. Ann N Y Acad Sci 2011; 1215:79-88. doi:10.1111/j.1749-6632.2010.05846.x, PMID:21261644.

[90]	Jin S, Wei J, You L, Liu H, Qian W. Autophagy regulation and its dual role in blood cancers: A novel target for therapeutic development (Re-view). Oncol Rep 2018; 39(6):2473-2481. doi:10.3892/or.2018.6370,PMID:29658589.

[91]	Barnard RA, Regan DP, Hansen RJ, Maycotte P, Thorburn A, Gustafson DL. Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease. J Pharmacol Exp Ther 2016; 358(2):282-293. doi:10.1124/jpet.116.233908,PMID:27231155.

[92]	Guo JY, Xia B, White E. Autophagy-mediated tumor promotion. Cell 2013; 155(6):1216-1219. doi:10.1016/j.cell.2013.11.019,PMID:24315093.

[93]	Long W, Zhang L, Wang Y, Xie H, Wang L, Yu H. Research Progress and Prospects of Autophagy in the Mechanism of Multidrug Resistance in Tumors. J Oncol 2022; 2022:7032614. doi:10.1155/2022/7032614,PMID:35136409.

[94]	White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12(6):401-410. doi:10.1038/nrc3262,PMID:22534666.

[95]	Ferraresi A, Girone C, Esposito A, Vidoni C, Vallino L, Secomandi E, et al. How Autophagy Shapes the Tumor Microenvironment in Ovarian Cancer. Front Oncol 2020;10:599915. doi:10.3389/fonc.2020.599915,PMID:33364196.

[96]	Wang Q, Bu S, Xin D, Li B, Wang L, Lai D. Autophagy Is Indispensable for the Self-Renewal and Quiescence of Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties. Oxid Med Cell Longev 2018; 2018:7010472. doi:10.1155/2018/7010472,PMID:30319732.

[97]	Li X, He S, Ma B. Autophagy and autophagy-related proteins in can-cer. Mol Cancer 2020; 19(1):12. doi:10.1186/s12943-020-1138-4,PMID:31969156.

[98]	Zhong LX, Zhang Y, Wu ML, Liu YN, Zhang P, Chen XY, et al. Resvera-trol and STAT inhibitor enhance autophagy in ovarian cancer cells. Cell Death Discov 2016;2:15071. doi:10.1038/cddiscovery.2015.71,PMID:27551495.

[99]	Ferraresi A, Esposito A, Girone C, Vallino L, Salwa A, Ghezzi I, et al. Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migra-tion and Platinum Resistance by Rescuing Hedgehog-Mediated Au-tophagy. Cells 2021; 10(11):3213. doi:10.3390/cells10113213,PMID:34831435.

[100]

Hu S, Li X, Xu R, Ye L, Kong H, Zeng X, et al. The synergistic effect of resveratrol in combination with cisplatin on apoptosis via modu-lating autophagy in A549 cells. Acta Biochim Biophys Sin (Shang-hai) 2016; 48(6):528-535. doi:10.1093/abbs/gmw026,PMID:27084520.

[101]

Vidoni C, Ferraresi A, Vallino L, Salwa A, Ha JH, Seca C, et al. Glyco-lysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol. Int J Mol Sci 2023; 24(2):1723. doi:10.3390/ijms24021723,PMID:36675246.

[102]

Opipari AW Jr, Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR. Resveratrol-induced autophagocytosis in ovarian cancer cells. Can-cer Res 2004; 64(2):696-703. doi:10.1158/0008-5472.can-03-2404,PMID:14744787.

[103]

Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr 2018; 58(9):1428-1447. doi:10.1080/10408398.2016.1263597,PMID:28001084.

[104]

Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, et al. Health benefits of resveratrol: Evidence from clinical studies. Med Res Rev 2019; 39(5):1851-1891. doi:10.1002/med.21565,PMID:30741437.

[105]

Elias KM, Guo J, Bast RC Jr. Early Detection of Ovarian Cancer. He-matol Oncol Clin North Am 2018; 32(6):903-914. doi:10.1016/j.hoc.2018.07.003, PMID:30390764.

[106]

Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoa-coustic imaging via nanotheranostics in fighting cancer. Chem Soc Rev 2019; 48(7):2053-2108. doi:10.1039/c8cs00618k,PMID:30259015.

[107]

Wang Y, Zhang H, Liu Y, Younis MH, Cai W, Bu W. Catalytic radiosen-sitization: Insights from materials physicochemistry. Mater Today (Kidlington) 2022; 57:262-278. doi:10.1016/j.mattod.2022.05.022,PMID:36425004.

[108]

Wang Z, Zhao Y, Yang Z, Li X, Xing H, Qu W, et al. Construction of Intelli-gent Responsive Drug Delivery System and Multi-Mode Imaging Based on Gold Nanodots. Macromol Rapid Commun 2022; 43(10):e2200034. doi:10.1002/marc.202200034,PMID:35332623.

[109]

Singh A, Guo Y, Cruz M, Shi D, Kitts DD, Pratap-Singh A. Chitosan/PEG na-noparticle-embedded oleogels improve blueberry derived resveratrol bioavailability and antioxidant capacity. Food Chem 2025;490:145038. doi:10.1016/j.foodchem.2025.145038,PMID:40505306.

[110]

Sun Z, Cheng K, Yao Y, Wu F, Fung J, Chen H, et al. Controlled Nano-Bio Interface of Functional Nanoprobes for in Vivo Monitoring Enzyme Activity in Tumors. ACS Nano 2019; 13(2):1153-1167. doi:10.1021/acsnano.8b05825,PMID:30673268.

[111]

Khatun M, Choudhury S, Liu B, Lemmens P, Pal SK, Mazumder S. Res-veratrol-ZnO nanohybrid enhanced anti-cancerous effect in ovar-ian cancer cells through ROS. RSC Adv 2016; 6(107):105607-105617. doi:10.1039/C6RA16664D.

[112]

Guo L, Peng Y, Li Y, Yao J, Zhang G, Chen J, et al. Cell death pathway induced by resveratrol-bovine serum albumin nanoparticles in a hu-man ovarian cell line. Oncol Lett 2015; 9(3):1359-1363. doi:10.3892/ol.2015.2851,PMID:25663913.

[113]

Long Q, Zhu W, Guo L, Pu L. RGD-Conjugated Resveratrol HSA Nano-particles as a Novel Delivery System in Ovarian Cancer Therapy. Drug Des Devel Ther 2020; 14:5747-5756. doi:10.2147/DDDT.S248950,PMID:33408463.

[114]

Chen Q, Gu P, Liu X, Hu S, Zheng H, Liu T, et al. Gold Nanoparticles Encapsulated Resveratrol as an Anti-Aging Agent to Delay Cataract Development. Pharmaceuticals (Basel) 2022; 16(1):26. doi:10.3390/ph16010026,PMID:36678523.

[115]

Wang M, Li L, Zhang X, Liu Y, Zhu R, Liu L, Fang Y, Gao Z, Gao D. Mag-netic resveratrol liposomes as a new theranostic platform for mag-netic resonance imaging guided Parkinson’s disease targeting ther-apy. ACS Sustain Chem Eng 2018; 6(12):17124-17133. doi:10.1021/acssuschemeng.8b04507.

[116]

Carlson LJ, Cote B, Alani AW, Rao DA. Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci 2014; 103(8):2315-2322. doi:10.1002/jps.24042,PMID:24914015.

[117]

Fatease AA, Shah V, Nguyen DX, Cote B, LeBlanc N, Rao DA, et al. Chemosensitization and mitigation of Adriamycin-induced cardio-toxicity using combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin in ovarian cancer. Na-nomedicine 2019; 19:39-48. doi:10.1016/j.nano.2019.03.011,PMID:31022465.

[118]

Weżgowiec J, Łapińska Z, Lamch Ł, Szewczyk A, Saczko J, Kulbacka J, et al. Cytotoxic Activity of Curcumin- and Resveratrol-Loaded Core-Shell Systems in Resistant and Sensitive Human Ovarian Cancer Cells. Int J Mol Sci 2024; 26(1):41. doi:10.3390/ijms26010041,PMID:39795900.

[119]

van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IJcken WF, Mathijssen RH, et al. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer 2015; 14:196. doi:10.1186/s12943-015-0464-4,PMID:26576679.

[120]

Cummings M, Freer C, Orsi NM. Targeting the tumour microenvironment in platinum-resistant ovarian cancer. Semin Cancer Biol 2021; 77:3-28. doi:10.1016/j.semcancer.2021.02.007,PMID:33607246.

[121]

Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive en-tity? Mol Cancer 2017; 16(1):64. doi:10.1186/s12943-017-0638-3,PMID:28320418.

[122]

Cragg GM, Pezzuto JM. Natural Products as a Vital Source for the Dis-covery of Cancer Chemotherapeutic and Chemopreventive Agents. Med Princ Pract 2016; 25(Suppl 2):41-59. doi:10.1159/000443404,PMID:26679767.

[123]

Catanzaro D, Gabbia D, Cocetta V, Biagi M, Ragazzi E, Montopoli M, et al. Silybin counteracts doxorubicin resistance by inhibiting GLUT 1 expres-sion. Fitoterapia 2018; 124:42-48. doi:10.1016/j.fitote.2017.10.007,PMID:29031537.

[124]

Montopoli M, Ragazzi E, Froldi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif 2009; 42(2):195-206. doi:10.1111/j.1365-2184.2009.00585.x, PMID:19236381.

[125]

Baatout S, Derradji H, Jacquet P, Ooms D, Michaux A, Mergeay M. En-hanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int J Mol Med 2004; 13(6):895-902. PMID:15138632.

[126]

Xu L, Yang X, Cai J, Ma J, Cheng H, Zhao K, et al. Resveratrol attenuates radiation-induced salivary gland dysfunction in mice. Laryngoscope 2013; 123(11):E23-E29. doi:10.1002/lary.24276, PMID:23794219.

[127]

Carsten RE, Bachand AM, Bailey SM, Ullrich RL. Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat Res 2008; 169(6):633-638. doi:10.1667/RR1190.1,PMID:18494544.

[128]

Wang L, Long L, Wang W, Liang Z. Resveratrol, a potential radia-tion sensitizer for glioma stem cells both in vitro and in vivo. J Phar-macol Sci 2015; 129(4):216-225. doi:10.1016/j.jphs.2015.11.001,PMID:26698406.

[129]

Mikami S, Ota I, Masui T, Uchiyama T, Okamoto H, Kimura T, et al. Resveratrol-induced REG III expression enhances chemo- and ra-diosensitivity in head and neck cancer in xenograft mice. Oncol Rep 2019; 42(1):436-442. doi:10.3892/or.2019.7137,PMID:31059079.

[130]

Chen YA, Lien HM, Kao MC, Lo UG, Lin LC, Lin CJ, et al. Sensitization of Radioresistant Prostate Cancer Cells by Resveratrol Isolated from Ara-chis hypogaea Stems. PLoS One 2017; 12(1):e0169204. doi:10.1371/journal.pone.0169204,PMID:28081154.

[131]

Zhang L, Ye B, Chen Z, Chen ZS. Progress in the studies on the molecu-lar mechanisms associated with multidrug resistance in cancers. Acta Pharm Sin B 2023; 13(3):982-997. doi:10.1016/j.apsb.2022.10.002,PMID:36970215.

[132]

Zhu X, Zhang W, Xiang H, Chang Q, Liu R, Wan Y, et al. Radiation-enhanced self-cascade catalytic Ti3C2Tx-based platform enables controlled release of trans-resveratrol for synergistic radiosensiti-zation against metastasis of orthotopic breast cancer. Nano Today 2023;50:101836. doi:10.1016/j.nantod.2023.101836.

[133]

El-Readi MZ, Eid S, Abdelghany AA, Al-Amoudi HS, Efferth T, Wink M. Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. Phy-tomedicine 2019; 55:269-281. doi:10.1016/j.phymed.2018.06.046,PMID:30668439.

[134]

Zhang B, Kang Z, Zhang J, Kang Y, Liang L, Liu Y, et al. Simultaneous bind-ing mechanism of multiple substrates for multidrug resistance trans-porter P-glycoprotein. Phys Chem Chem Phys 2021; 23(8):4530-4543. doi:10.1039/d0cp05910b,PMID:33595579.

[135]

Zhang Y, Zhang Z, Mousavi M, Moliani A, Bahman Y, Bagheri H. Res-veratrol inhibits glioblastoma cells and chemoresistance progression through blockade P-glycoprotein and targeting AKT/PTEN signal-ing pathway. Chem Biol Interact 2023;376:110409. doi:10.1016/j.cbi.2023.110409.

[136]

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and fu-ture. Cell Death Dis 2014; 5(5):e1257. doi:10.1038/cddis.2013.428,PMID:24874729.

[137]

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molec-ular mechanisms of cisplatin resistance. Oncogene 2012; 31(15):1869-1883. doi:10.1038/onc.2011.384,PMID:21892204.

[138]

Cocetta V, Ragazzi E, Montopoli M. Links between cancer metabo-lism and cisplatin resistance. Int Rev Cell Mol Biol 2020; 354:107-164. doi:10.1016/bs.ircmb.2020.01.005,PMID:32475471.

[139]

Nessa MU, Beale P, Chan C, Yu JQ, Huq F. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anti-cancer Res 2012; 32(1):53-59. PMID:22213288.

[140]

Engelke LH, Hamacher A, Proksch P, Kassack MU. Ellagic Acid and Res-veratrol Prevent the Development of Cisplatin Resistance in the Epi-thelial Ovarian Cancer Cell Line A2780. J Cancer 2016; 7(4):353-363. doi:10.7150/jca.13754,PMID:26918049.

[141]

McMullen M, Madariaga A, Lheureux S. New approaches for tar-geting platinum-resistant ovarian cancer. Semin Cancer Biol 2021; 77:167-181. doi:10.1016/j.semcancer.2020.08.013,PMID:32871277.

[142]

Khan IU, Khan RU, Asif H, Alamgeer, Khalid SH, Asghar S, et al. Co-de-livery strategies to overcome multidrug resistance in ovarian cancer. Int J Pharm 2017; 533(1):111-124. doi:10.1016/j.ijpharm.2017.09.060,PMID:28947245.

[143]

Sohn EJ. PIK3R3, a regulatory subunit of PI3K, modulates ovarian can-cer stem cells and ovarian cancer development and progression by in-tegrative analysis. BMC Cancer 2022; 22(1):708. doi:10.1186/s12885-022-09807-7,PMID:35761259.

[144]

Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, ran-domised, double-blind, placebo-controlled, phase 2 trial. Lancet On-col 2018;19(9):1247-1258. doi:10.1016/S1470-2045(18)30372-3, PMID:30100379.

[145]

Zahra M, Shah M, Ahmad F, Zulfiqar F, Tariq A, Iqbal N. A randomized controlled trial comparing the efficacy of resveratrol combined with metformin versus resveratrol monotherapy in the management of polycystic ovary syndrome. Naunyn Schmiedebergs Arch Pharmacol 2025. doi:10.1007/s00210-025-04495-z,PMID:40888876.

[146]

Mansour A, Samadi M, Sanginabadi M, Gerami H, Karimi S, Hosseini S, et al. Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS. Clin Nutr 2021; 40(6):4106-4112. doi:10.1016/j.clnu.2021.02.004,PMID:33610422.

[147]

Bahramrezaie M, Amidi F, Aleyasin A, Saremi A, Aghahoseini M, Bren-jian S, et al. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory param-eters of polycystic ovary syndrome: a triple-blind randomized clini-cal trial. J Assist Reprod Genet 2019; 36(8):1701-1712. doi:10.1007/s10815-019-01461-6,PMID:31327131.

[148]

Banaszewska B, Wrotyńska-Barczyńska J, Spaczynski RZ, Pawelczyk L, Duleba AJ. Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. J Clin Endo-crinol Metab 2016; 101(11):4322-4328. doi:10.1210/jc.2016-1858,PMID:27754722.